Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously
address different antigens or epitopes. BsAbs with 'two-target'functionality can interfere with …

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

Bispecific antibodies (bsAbs) bind two different epitopes on the same or different antigens.
Through this dual specificity for soluble or cell-surface antigens, bsAbs exert activities …

ABSTRACT A bispecific antibody (bsAb) is able to bind two different targets or two distinct
epitopes on the same target. Broadly speaking, bsAbs can include any single molecule …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Development of bispecific antibodies (BsAbs) as therapeutic agents has recently attracted
significant attention, and investments in this modality have been steadily increasing. This …

Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and
infectious diseases and other disorders. Most of the marketed antibodies are monospecific …

Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different
antigens or two different epitopes on the same antigen. The clinical therapeutic effects of …

Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …